An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) announced that Giles Campion, MD, will participate in a fireside chat at the Chardan Genetic Medicines Conference on October 4 at 3:45 p.m. ET in New York. The event can be viewed live on the company's website. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet medical needs, leveraging its mRNAi GOLD™ platform. Major products include SLN360 for cardiovascular risk and SLN124 for rare hematological diseases. Collaborations with AstraZeneca and others enhance their research efforts.
Positive
None.
Negative
None.
LONDON--(BUSINESS WIRE)--
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on Tuesday, October 4th at 3:45 p.m. ET in New York.
A live webcast of the fireside chat will be available on the Investors section of the Silence website at www.silence-therapeutics.com.
About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
